garenoxacin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibacterials, nalidixic acid derivatives | 4053 | 194804-75-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
a des-fluoro(6) quinolone with antibacterial activity
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.40 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 1 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 1.23 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.25 % | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 10 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Bocci G, Oprea TI, Benet LZ |
| BA (Bioavailability) | 0.92 % | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 30, 2007 | PMDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Interstitial lung disease | 44.93 | 39.21 | 21 | 663 | 112579 | 79631125 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01MA19 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE QUINOLONE ANTIBACTERIALS Fluoroquinolones |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D059005 | Topoisomerase II Inhibitors |
| MeSH PA | D059003 | Topoisomerase Inhibitors |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory agent |
| CHEBI has role | CHEBI:36047 | antibacterial drugs |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Peritonsillar abscess | indication | 15033003 | |
| Sinusitis | indication | 36971009 | |
| Bacterial pneumonia | indication | 53084003 | DOID:874 |
| Infective otitis media | indication | 312218008 | |
| Infective laryngitis | indication | 312423006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 6.37 | acidic |
| pKa2 | 8.85 | Basic |
| pKa3 | 0.41 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D02540 | KEGG_DRUG |
| C1507405 | UMLSCUI |
| CHEBI:131716 | CHEBI |
| CHEMBL215303 | ChEMBL_ID |
| DB06160 | DRUGBANK_ID |
| C419689 | MESH_SUPPLEMENTAL_RECORD_UI |
| 124093 | PUBCHEM_CID |
| 12402 | IUPHAR_LIGAND_ID |
| 8237 | INN_ID |
| 223652-90-2 | SECONDARY_CAS_RN |
| V72H9867WB | UNII |
| CHEMBL3183451 | ChEMBL_ID |
Pharmaceutical products:
None